CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients

Clinical Immunology

Volumn 179, Issue , 2017, Pages 40-46

  Kohler, Siegfried ^a   Keil, Thomas Oskar Philipp ^a   Hoffmann, Sarah ^a   Swierzy, Marc ^a   Ismail, Mahmoud ^a   Rückert, Jens Carsten ^a   Alexander, Tobias ^a   Meisel, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Autoimmunity; Myasthenia gravis; Regulatory T cells; Thymus

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; METHOTREXATE; MYCOPHENOLATE MOFETIL; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ELECTROPHYSIOLOGICAL PROCEDURES; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THYMECTOMY; THYMOMA; THYMUS HYPERPLASIA; THYMUS TISSUE; TREATMENT RESPONSE; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; THYMUS; THYMUS NEOPLASMS;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; THYMECTOMY; THYMOMA; THYMUS GLAND; THYMUS HYPERPLASIA; THYMUS NEOPLASMS;

EID: 85015389610     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2017.03.003     Document Type: Article

References (41)

1. [1] Conti-Fine, B.M., Milani, M., Kaminski, H.J., Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006), 2843–2854.
2. [2] J.P. Sieb, Myasthenia gravis: an update for the clinician, Clin. Exp. Immunol., 175 408–418.
3. [3] M. Miyara, G. Gorochov, M. Ehrenstein, L. Musset, S. Sakaguchi, Z. Amoura, Human FoxP3 + regulatory T cells in systemic autoimmune diseases, Autoimmun. Rev., 10 744–755.
4. [4] S. Gertel-Lapter, K. Mizrachi, S. Berrih-Aknin, S. Fuchs, M.C. Souroujon, Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model, Autoimmun. Rev., 12 894–903.
5. [5] V. Nessi, S. Nava, C. Ruocco, C. Toscani, R. Mantegazza, C. Antozzi, F. Baggi, Naturally occurring CD4 + CD25 + regulatory T cells prevent but do not improve experimental myasthenia gravis, J. Immunol., 185 5656–5667.
6. [6] Aricha, R., Feferman, T., Fuchs, S., Souroujon, M.C., Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J. Immunol. 180 (2008), 2132–2139.
7. [7] Balandina, A., Lecart, S., Dartevelle, P., Saoudi, A., Berrih-Aknin, S., Functional defect of regulatory CD4(+)CD25 + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105 (2005), 735–741.
8. [8] Scarpino, S., Di Napoli, A., Stoppacciaro, A., Antonelli, M., Pilozzi, E., Chiarle, R., Palestro, G., Marino, M., Facciolo, F., Rendina, E.A., Webster, K.E., Kinkel, S.A., Scott, H.S., Ruco, L., Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin. Exp. Immunol. 149 (2007), 504–512.
9. [9] Strobel, P., Rosenwald, A., Beyersdorf, N., Kerkau, T., Elert, O., Murumagi, A., Sillanpaa, N., Peterson, P., Hummel, V., Rieckmann, P., Burek, C., Schalke, B., Nix, W., Kiefer, R., Muller-Hermelink, H.K., Marx, A., Selective loss of regulatory T cells in thymomas. Ann. Neurol. 56 (2004), 901–904.
10. [10] Fattorossi, A., Battaglia, A., Buzzonetti, A., Minicuci, G., Riso, R., Peri, L., Scambia, G., Evoli, A., Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy. J. Clin. Immunol. 28 (2008), 194–206.
11. [11] N. Matsui, S. Nakane, F. Saito, I. Ohigashi, Y. Nakagawa, H. Kurobe, H. Takizawa, T. Mitsui, K. Kondo, T. Kitagawa, Y. Takahama, R. Kaji, Undiminished regulatory T cells in the thymus of patients with myasthenia gravis, Neurology, 74 816–820.
12. [12] Sun, Y., Qiao, J., Lu, C.Z., Zhao, C.B., Zhu, X.M., Xiao, B.G., Increase of circulating CD4 + CD25 + T cells in myasthenia gravis patients with stability and thymectomy. Clin. Immunol. 112 (2004), 284–289.
13. [13] Huang, Y.M., Pirskanen, R., Giscombe, R., Link, H., Lefvert, A.K., Circulating CD4 + CD25 + and CD4 + CD25 + T cells in myasthenia gravis and in relation to thymectomy. Scand. J. Immunol. 59 (2004), 408–414.
14. [14] M. Thiruppathi, J. Rowin, B. Ganesh, J.R. Sheng, B.S. Prabhakar, M.N. Meriggioli, Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/−) T cells in patients with myasthenia gravis, Clin. Immunol., 145 209–223.
15. [15] M. Thiruppathi, J. Rowin, Q. Li Jiang, J.R. Sheng, B.S. Prabhakar, M.N. Meriggioli, Functional defect in regulatory T cells in myasthenia gravis, Ann. N. Y. Acad. Sci., 1274 68–76.
16. [16] Luther, C., Adamopoulou, E., Stoeckle, C., Brucklacher-Waldert, V., Rosenkranz, D., Stoltze, L., Lauer, S., Poeschel, S., Melms, A., Tolosa, E., Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J. Immunol. 183 (2009), 841–848.
17. [17] Kleinewietfeld, M., Starke, M., Di Mitri, D., Borsellino, G., Battistini, L., Rotzschke, O., Falk, K., CD49d provides access to “untouched” human Foxp3 + Treg free of contaminating effector cells. Blood 113 (2009), 827–836.
18. [18] Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., Mathian, A., Nakahata, T., Yamaguchi, T., Nomura, T., Ono, M., Amoura, Z., Gorochov, G., Sakaguchi, S., Functional delineation and differentiation dynamics of human CD4 + T cells expressing the FoxP3 transcription factor. Immunity 30 (2009), 899–911.
19. [19] K. Akesson, A. Tompa, A. Ryden, M. Faresjo, Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+)/CD129(+) on Treg cells in children with coeliac disease, Clin. Exp. Immunol., 180 70–82.
20. [20] Haas, J., Fritzsching, B., Trubswetter, P., Korporal, M., Milkova, L., Fritz, B., Vobis, D., Krammer, P.H., Suri-Payer, E., Wildemann, B., Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J. Immunol. 179 (2007), 1322–1330.
21. [21] A.M. Thornton, P.E. Korty, D.Q. Tran, E.A. Wohlfert, P.E. Murray, Y. Belkaid, E.M. Shevach, Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3 + T regulatory cells, J. Immunol., 184 3433–3441.
22. [22] A. Marx, F. Pfister, B. Schalke, G. Saruhan-Direskeneli, A. Melms, P. Strobel, The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes, Autoimmun. Rev., 12 875–884.
23. [23] I. Caramalho, H. Nunes-Cabaco, R.B. Foxall, A.E. Sousa, Regulatory T-Cell Development in the Human Thymus, Front. Immunol., 6 395.
24. [24] Okumura, M., Miyoshi, S., Fujii, Y., Takeuchi, Y., Shiono, H., Inoue, M., Fukuhara, K., Kadota, Y., Tateyama, H., Eimoto, T., Matsuda, H., Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am. J. Surg. Pathol. 25 (2001), 103–110.
25. [25] Okumura, M., Ohta, M., Tateyama, H., Nakagawa, K., Matsumura, A., Maeda, H., Tada, H., Eimoto, T., Matsuda, H., Masaoka, A., The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94 (2002), 624–632.
26. [26] Watanabe, N., Wang, Y.H., Lee, H.K., Ito, T., Wang, Y.H., Cao, W., Liu, Y.J., Hassall's corpuscles instruct dendritic cells to induce CD4 + CD25 + regulatory T cells in human thymus. Nature 436 (2005), 1181–1185.
27. [27] Annunziato, F., Cosmi, L., Liotta, F., Lazzeri, E., Manetti, R., Vanini, V., Romagnani, P., Maggi, E., Romagnani, S., Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J. Exp. Med. 196 (2002), 379–387.
28. [28] Himmel, M.E., MacDonald, K.G., Garcia, R.V., Steiner, T.S., Levings, M.K., Helios + and Helios- cells coexist within the natural FOXP3 + T regulatory cell subset in humans. J. Immunol., 190, 2001–2008.
29. [29] Verhagen, J., Wraith, D.C., Comment on Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.; author reply 7130. J. Immunol., 185(12), 2010 Dec 15, 7129, 10.4049/jimmunol.1090105 PubMed PMID: 21127313.
30. [30] Cea, G., Benatar, M., Verdugo, R.J., Salinas, R.A., Thymectomy for non-thymomatous myasthenia gravis. CD008111 Cochrane Database Syst Rev.(10), 2013 Oct 14, 10.1002/14651858.CD008111.pub2 Review. PubMed PMID: 24122674.
31. [31] Wolfe, G.I., Kaminski, H.J., Cutter, G.R., et al. Randomized trial of thymectomy in myasthenia gravis. N. Engl. J. Med. 375 (2016), 2006–2007.
32. [32] Fattorossi, A., Battaglia, A., Buzzonetti, A., Ciaraffa, F., Scambia, G., Evoli, A., Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116 (2005), 134–141.
33. [33] K.G. Schmetterer, A. Neunkirchner, W.F. Pickl, Naturally occurring regulatory T cells: markers, mechanisms, and manipulation, FASEB J., 26 2253–2276.
34. [34] A.W. Schadenberg, T. van den Broek, M.A. Siemelink, S.O. Algra, P.R. de Jong, N.J. Jansen, B.J. Prakken, F. van Wijk, Differential homeostatic dynamics of human regulatory T-cell subsets following neonatal thymectomy, J. Allergy Clin. Immunol., 133 277–280 e271-276.
35. [35] Alarcon Segovia, D., Galbraith, R.F., Maldonado, J.E., Howard, F.M. Jr., Systemic lupus erythematosus following thymectomy for mysthenia gravis. Report of two cases. Lancet 2 (1963), 662–665.
36. [36] Petersen, P., Lund, J., Systemic lupus erythematosus following thymectomy for myasthenia gravis. Dan. Med. Bull. 16 (1969), 179–181.
37. [37] Galbraith, R.F., Summerskill, W.H., Murray, J., Systemic lupus erythematosus, cirrhosis and ulcerative colitis after thymectomy for myasthenia gravis. N. Engl. J. Med. 270 (1964), 229–231.
38. [38] Calabrese, L.H., Bach, J.F., Currie, T., Vidt, D., Clough, J., Krakauer, R.S., Development of systemic lupus erythematosus after thymectomy for myasthenia gravis. Studies of suppressor cell function. Arch. Intern. Med. 141 (1981), 253–255.
39. [39] Grinlinton, F.M., Lynch, N.M., Hart, H.H., A pair of monozygotic twins who are concordant for myasthenia gravis but became discordant for systemic lupus erythematosus post-thymectomy. Arthritis Rheum. 34 (1991), 916–919.
40. [40] Mevorach, D., Perrot, S., Buchanan, N.M., Khamashta, M., Laoussadi, S., Hughes, G.R., Menkes, C.J., Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature. Lupus 4 (1995), 33–37.
41. [41] H.A. Omar, M.A. Alzahrani, A.A. Al Bshabshe, A. Assiri, M. Shalaby, A. Dwedar, S.R. Abdulwahed, M.R. Hussein, Systemic lupus erythematosus after thymectomy for myasthenia gravis: a case report and review of the literature, Clin. Exp. Nephrol., 14 272–276.